223253-64-3

Upstream product

• 54013-91-1 2-(1-methylethoxy)phenyl-1-piperazine 
• 540-51-2 2-bromoethanol 

Downstream Products

• 223254-30-6 1-{4-hydroxy-5-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pentyl}-piperidin-2-one 
• 223253-70-1 [4-(2-isopropoxy-phenyl)-piperazin-1-yl]-acetaldehyde 

Relevant academic research and scientific papers

Heterocycles useful in the treatment of benign prostatic hyperplasia

This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

Novel arylpiperazines as selective α1-adrenergic receptor antagonists

A novel series of arylpiperazines has been synthesized and identified as antagonists of α(1a) adrenergic receptor (α(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound α(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known α1-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

Novel heterocycles as selective α1-adrenergic receptor antagonists

A novel series of aryl piperazine substituted heterocycles has been synthesized and identified as antagonists of the α(1a)-adrenergic receptor (α(1a)-AR), which has been implicated in benign prostatic hyperplasia (BPH). These compounds selectively inhibit binding to the α(1a)-AR with K(i)s as low as 2.1 nM. (C) 2000 Elsevier Science Ltd.